Search

Your search keyword '"Barbini, B"' showing total 252 results
Start Over Author "Barbini, B" Search Limiters Academic (Peer-Reviewed) Journals
252 results on '"Barbini, B"'

2. Mood Disorders

Author

Franchini, L., Barbini, B., Zanardi, R., Fregna, L., Martini, F., Manfredi, E., Sarzetto, A., Maiocchi, B., Ragone, N., Colombo, C., Cavallaro, Roberto, editor, and Colombo, Cristina, editor

Published
2022
Full Text
View/download PDF

3. Non-Pharmacological Treatments

Author

Barbini, B., Seghi, F., Bosia, M., Fregna, L., Martini, F., Attanasio, F., Manfredi, E., Vassena, G., Colombo, C., Cavallaro, R., Cavallaro, Roberto, editor, and Colombo, Cristina, editor

Published
2022
Full Text
View/download PDF

7. P.253 Immunoassay quantification and neuroimaging data for differentiating bipolar and unipolar depression: support vector machine on kernels and elastic net approaches

Author

Vai, B., primary, Parenti, L., additional, Cazzetta, S., additional, Mazza, M., additional, Bollettini, I., additional, Poletti, S., additional, Lorenzi, C., additional, Aggio, V., additional, Zanardi, R., additional, Barbini, B., additional, Colombo, C., additional, and Benedetti, F., additional

Published
2020
Full Text
View/download PDF

13. Bone mineral density, kidney function, weight gain and insulin resistance in women who switch from TDF/FTC/NNRTI to ABC/3TC/DTG.

Author

Ibrahim, F, Samarawickrama, A, Hamzah, L, Vincent, R, Gilleece, Y, Waters, L, Kegg, S, Barbini, B, Campbell, L, and Post, FA

Subjects
SPINE physiology, BIOMARKERS, FEMUR neck, HIP joint, HOMEOSTASIS, INSULIN resistance, KIDNEYS, REGRESSION analysis, RESEARCH, TIME, WOMEN'S health, WEIGHT gain, METABOLIC syndrome, BONE density, RANDOMIZED controlled trials, TREATMENT effectiveness, ABACAVIR-lamivudine (Drug), EMTRICITABINE-tenofovir, HIV integrase inhibitors, DESCRIPTIVE statistics, CD4 lymphocyte count, PHOTON absorptiometry
Abstract

Objectives: Tenofovir disoproxil fumarate (TDF) is associated with reduced bone mineral density (BMD). We evaluated changes in BMD in women who switched from TDF, emtricitabine and a nonnucleoside reverse transcriptase inhibitor (TDF/FTC/NNRTI) to abacavir, lamivudine and dolutegravir (ABC/3TC/DTG). Methods: We conducted a randomized controlled trial in which women aged ≥40 years were randomized 1:2 to continue TDF/FTC/NNRTI or switch to ABC/3TC/DTG. The primary endpoint was change in total hip BMD measured by dual‐energy X‐ray absorptiometry at week 48. Secondary endpoints were changes in BMD of the lumbar spine and femoral neck and markers of bone turnover and kidney function up to week 48. We conducted exploratory analyses of weight gain, insulin resistance and metabolic syndrome. Primary and secondary endpoints were analysed by linear regression, with multiple imputation for missing time points. Results: In all, 91 women [mean age = 50.4 (standard deviation [SD] = 6.6) years, median CD4 cell count = 600 (interquartile range: 479–800) cells/µL] were randomized. Women who switched to ABC/3TC/DTG maintained viral suppression and experienced improvements in total hip BMD (mean adjusted difference = 1%, P = 0.027) and lumbar spine BMD (3%, P = 0.002), with no change in specific markers of bone turnover or renal tubular function. Although participants in the ABC/3TC/DTG arm gained more weight (1.8 kg, P = 0.046), the switch strategy was not associated with reduced insulin sensitivity or new‐onset metabolic syndrome. Conclusions: Switching from TDF/FTC/NNRTI to ABC/3TC/DTG resulted in improved BMD. Although weight gain was common in women who switched from TDF/FTC/NNRTI to ABC/3TC/DTG, we did not detect adverse effects on glucose homeostasis. Larger studies need to confirm these findings. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

14. Early safety of tenofovir alafenamide in patients with a history of tubulopathy on tenofovir disoproxil fumarate: a randomized controlled clinical trial.

Author

Hamzah, L, Williams, D, Bailey, AC, Jones, R, Ibrahim, F, Musso, CG, Burling, K, Barbini, B, Campbell, L, and Post, FA

Subjects
BONE physiology, KIDNEY physiology, BIOMARKERS, CARRIER proteins, COMPARATIVE studies, CONFIDENCE intervals, CREATININE, GLOMERULAR filtration rate, HIV infections, KIDNEY tubules, KIDNEY diseases, HEALTH outcome assessment, PATIENT safety, REGRESSION analysis, STATISTICAL sampling, TIME, VITAMIN A, ANTIRETROVIRAL agents, TERMINATION of treatment, RANDOMIZED controlled trials, PRE-tests & post-tests, REPEATED measures design, CYSTATINS, FANCONI syndrome, EMTRICITABINE, TENOFOVIR, NUCLEOSIDE reverse transcriptase inhibitors, DESCRIPTIVE statistics, URINE
Abstract

Objectives: The aim of the study was to assess the effect of tenofovir alafenamide (TAF) on kidney and bone biomarkers in patients who developed proximal renal tubulopathy (PRT) while receiving tenofovir disoproxil fumarate (TDF). Methods: Individuals with a history of TDF‐associated PRT and currently suppressed HIV infection on a tenofovir‐sparing regimen were randomized 1:1 to continue current antiretroviral therapy or initiate emtricitabine (F)/TAF with discontinuation of nucleoside reverse transcriptase inhibitors (NRTIs) as appropriate. Renal and bone biomarkers were analysed at baseline, week 4 and week 12. The primary outcome was the mean difference between study arms in urine retinol‐binding protein:creatinine ratio (RBPCR) change from baseline to week 12. Data were analysed using linear regression, with robust standard errors (primary outcome), and repeated measures mixed effects models (secondary outcomes). The trial was registered under European Union Drug Regulating Authorities Clinical Trials Database 2016‐003345‐29. Results: We randomized 31 individuals [mean age 52.4 (standard deviation 0.3) years; 97% male; 90% white); all completed the study. At 12 weeks, there was no difference in change in RBPCR (β 19.6; 95% confidence interval −35.3, 74.5; P = 0.47), and no difference in change in estimated glomerular filtration rate (eGFR) (based on creatinine or cystatin C), albuminuria, proteinuria, renal phosphate or urea handling, (fasting) urine osmolality, parathyroid hormone and bone turnover markers in the control versus the F/TAF exposed groups. No cases of PRT were observed. Conclusions: In people with a history of proximal renal tubulopathy while on TDF, 12‐week exposure to TAF did not adversely affect renal tubular function. These data support continued evaluation of the long‐term safety of TAF in this group of patients. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

22. Seasonality in mood disorders: clinical and genetic aspects

Author

Brambilla C, Locatelli C, Gavinelli C, Cigala Fulgosi M, Lorenzi C, Pirovano A, Barbini B, COLOMBO , CRISTINA ANNA, Brambilla, C, Locatelli, C, Gavinelli, C, Cigala Fulgosi, M, Lorenzi, C, Pirovano, A, Barbini, B, and Colombo, CRISTINA ANNA

Published
2011

37. Cognitive assessment of depression: a new test for mood disorders

Author

Benedetti F, Barbini B, Cigala Fulgosi M, Pontiggia A, Smeraldi E., BENEDETTI, FRANCESCO, COLOMBO , CRISTINA ANNA, Benedetti, F, Barbini, B, Cigala Fulgosi, M, Pontiggia, A, Colombo, CRISTINA ANNA, Smeraldi, E., and Benedetti, Francesco

Subjects
Major depression Diagnosis Neuropsychological assessment
Abstract

Object: Current methods of assessment of major depression are biased by consistent discordancies between self- andobserver-ratings of depression. Cognitive distortions are a regular core symptom of major depression, and are associated withthe development of hopelessness and suicidality.Method: Based on previous studies showing that patients who were diagnosed with major depressive disorders deniedpositive statements and endorsed more negative statements about themselves than normal subjects, we developed a computer-ized test with two tasks: a self-description task during which subjects were asked to self-attribute or refuse positive and negativeadjectives, and a recognition memory task during which subjects were asked to recognize the same adjectives randomly mixedwith semantically similar others. We tested 294 normal subjects and 247 patients affected by a major depressive episode.Results: In normal subjects frequencies and latencies of both self-attribution and recognition of positive stimuli wereenhanced in respect to negative stimuli, while in depressed patients negative self-scheme elements predominated in self-description, and information processing was slower for positive and negative elements. Single output measures were com-bined in a single score (named depressive differential) based on canonical coefficients derived from discriminant functionanalysis, which could correctly classify 92% of patients and 98% of controls. ROC analysis of depressive differential scoresshowed AUC=0.987, and two-graphs ROC analysis estimated sensitivity and specificity at 0.955 for the optimal cutoff value.Internal and external validity testing showed high correlations both with commonly used psychiatric rating scales and withinstruments specifically developed to assess depressive cognitive style. Test-retest reliability was high.Conclusions: Further studies will define the diagnostic power in respect to depressive syndromes pertaining to diagnosesother than mood disorders, and will precise if, and when, the observed distortions normalize during antidepressant treatment

Published
2005

39. Treatment: rapid improvement in information processing after sleep deprivation and sleep-phase advance in bipolar depression

Author

Benedetti F, Barbini B, Florita M, Cigala Fulgosi M, Pontiggia A, Campori E, Colombo C, Smeraldi E, Benedetti, F, Barbini, B, Florita, M, Cigala Fulgosi, M, Pontiggia, A, Campori, E, Colombo, C, and Smeraldi, E

Subjects
Sleep deprivation Sleep phase-advance Cingulate cortex Signal detection Self-schema
Abstract

Object: Sleep phase advance can prevent and substain the antidepressant effect of total sleep deprivation. Weevaluate the neuropsychological assessment during this cronotherapeutic procedureMethod: We tested self-description and recognition memory in 23 bipolar depressed inpatients treated with totalsleep deprivation followed by sleep phase-advance.Results: Treatment reverted and normalized the baseline biases toward negative stimuli.Conclusions: Changes in neuropsychological performance paralleled changes of mood, and could be explainedby treatment effects on anterior cingulate cortex metabolism

Published
2005

40. Cronoterapia clinica dei disturbi dell’umore

Author

Benedetti F, Barbini B, Pontiggia A, Cigala Fulgosi M, Bernasconi A., COLOMBO , CRISTINA ANNA, Benedetti, F, Colombo, CRISTINA ANNA, Barbini, B, Pontiggia, A, Cigala Fulgosi, M, and Bernasconi, A.

Published
2005

45. Chronobiological treatment of bipolar depression

Author

Benedetti E, Pontiggia A, Bernasconi A, Barbini B, Smeraldi E., COLOMBO , CRISTINA ANNA, Benedetti, E, Colombo, CRISTINA ANNA, Pontiggia, A, Bernasconi, A, Barbini, B, and Smeraldi, E.

Published
2003

50. Deprivazione di sonno e disturbo bipolare

Author

Benedetti F, Barbini B, Campori E, Cigala Fulgosi M, Smeraldi E., COLOMBO , CRISTINA ANNA, Benedetti, F, Barbini, B, Campori, E, Cigala Fulgosi, M, Colombo, CRISTINA ANNA, and Smeraldi, E.

Published
2001

Catalog

Books, media, physical & digital resources
See catalog results